CNA
CNA Financial Corporation
CNA trails on the overall score without a compensating advantage in the available component scores.
JPM
JPMorgan Chase & Co.
JPM has the edge over CNA overall, supported by stronger modeled upside and stronger fundamentals.
CNA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| N/A | |
| N/A |
CNA's profitability is currently healthy, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like CNA.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
CNA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.8x | $37.32 | -23% |
| Fair | 11x | $42.60 | -12% |
| Forward | 11x | $48.29 | — |
| Current | 13x | $48.29 | — |
| Expensive | 15x | $55.76 | +15% |
Historical ranges are pointers, not guarantees.
CNA has the edge over JPM in the historical PE scenario, which offers more potential upside but is not a forecast.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM's PE is in its expensive range at 14.4x. If earnings grow as analysts expect, today's price would be 13.7x next year's earnings.
CNA Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Decline | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect CNA's revenue to grow, but its earnings and profitability to decline.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for JPM, with profitability improving.
CNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.59 | +21% |
| Q3 2026 | $3.79 | +3.8% |
| Q2 2026 | $4.55 | +42% |
| Q1 2026 | $4.47 | +36% |
| Q4 2025 | $4.69 | +33% |
| Q3 2025 | $3.65 | -24% |
| Q2 2025 | $3.21 | -32% |
| Q1 2025 | $3.28 | -28% |
| Q4 2024 | $3.52 | -21% |
CNA earned $3.79 per share over the past year, up 3.8% from the year before.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM has the edge over CNA on earnings, with more consistent year-over-year improvement.
CNA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.8B | +0.1% |
| Q2 2026 | $3.8B | +3% |
| Q1 2026 | $3.7B | +1.4% |
| Q4 2025 | $3.8B | +3.8% |
| Q3 2025 | $3.8B | +5.5% |
| Q2 2025 | $3.7B | +5.6% |
| Q1 2025 | $3.6B | +5.3% |
| Q4 2024 | $3.7B | +5.2% |
CNA's revenue has grown year over year for 16 quarters in a row: $3.8B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.2% | -7.2 points |
| Q2 2026 | 11% | +0.4 points |
| Q1 2026 | 7.3% | -2.4 points |
| Q4 2025 | 9.9% | +9.3 points |
| Q3 2025 | 13% | +3.5 points |
| Q2 2025 | 10% | -1.2 points |
| Q1 2025 | 9.6% | -2.8 points |
| Q4 2024 | 0.6% | -13 points |
CNA's operating margin was 6.2% last quarter, down 7.2 points from the same quarter a year ago.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM's revenue has grown year over year for five quarters in a row: $50.2B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM has the edge over CNA on profitability, with a higher operating margin.
CNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $634M | -9.9% |
| Q2 2026 | $629M | +17% |
| Q1 2026 | $380M | -39% |
| Q4 2025 | $542M | -18% |
| Q3 2025 | $704M | -3.6% |
| Q2 2025 | $538M | -9.9% |
| Q1 2025 | $620M | +28% |
| Q4 2024 | $665M | +34% |
CNA has the edge over JPM on cash generation, producing positive trailing cash flow while its opponent burns cash.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
CNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +300K shares |
| 1 year | -0.1% | -300K shares |
| 3 years | -0.1% | -300K shares |
| 5 years | -0.3% | -700K shares |
| Available history | -0.2% | -500K shares |
CNA has 272M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $36M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $34M |
| Q4 2024 | — |
CNA spent $36M buying back its own shares over the past year, up 5.9% from the year before.
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has the edge over CNA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
CNA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.9x | Healthy |
| Q2 2026 | 1.6x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 2.2x | Moderate |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 2.1x | Moderate |
| Q4 2024 | 2.0x | Healthy |
CNA's net debt is about 1.9 years of its operating earnings (EBITDA), down from 2.2 years a year ago. Net leverage isn't a meaningful measure for financial services companies like CNA.
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM has the edge over CNA on leverage, with a lower net debt burden relative to earnings.
CNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.0 | Neutral |
| Stochastic | 35.9 | Neutral |
CNA's weekly RSI is 51 (neutral) and its Stochastic is 36 (neutral).
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
CNA PE vs Financial Services Sector
| Metric | CNA | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 2.2% below |
| PE % | 68 | 63 | 5 pts above |
CNA has the edge over JPM on valuation relative to its sector.
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM is trading at 14x earnings, a 10% premium to the Financial Services sector's median of 13x.
CNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.4 | 1.9% above |
| 20 week MA | $49.3 | 2% below |
| 50 week MA | $47.6 | 1.5% above |
| 100 week MA | $47.4 | 1.9% above |
| 200 week MA | $45.4 | 6.4% above |
CNA's trend is mixed: it's above four of its five weekly moving averages, and 6.4% above its 200-week average.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM's trend is mixed: it's above four of its five weekly moving averages, and 45% above its 200-week average.
CNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.5 | $38.6 | -13% |
| 2021 | $38.6 | $43.8 | +13% |
| 2022 | $43.8 | $41.9 | -4.4% |
| 2023 | $41.9 | $42.3 | +1.1% |
| 2024 | $42.3 | $48.4 | +14% |
| 2025 | $48.4 | $47.8 | -1.3% |
| 2026 YTD | $47.8 | $48.3 | +1.1% |
CNA has finished lower in three of the last six years. It's up 1.1% so far in 2026.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has the edge over CNA on returns for 2026, with the stronger performance.